Vabysmo is a bispecific antibody designed to inhibit vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2).

OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the ...

A new clinical study published in the Romanian Journal of Ophthalmology revealed that low-dose atorvastatin (10–20 mg) used ...

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...

Valiltramiprosate is associated with low ARIA rates and is well tolerated in APOE ε4 homozygotes with early Alzheimer disease ...

The FDA approved an updated label for Vabysmo for the treatment of macular edema following retinal vein occlusion beyond 6 ...

Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic diseases, today announced that it has completed ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing investigational therapies for patients with Alzheimer’s ...

Fenerbahçe announced that Marco Asensio's left knee anterior cruciate ligament strain and edema were detected. "As a result of the examinations carried out on Marco Asensio, the player of our Football ...

Three world-leading key opinion leaders, researchers and clinicians, join Clinical Advisory Board, reinforcing Bioxodes' global registrational clinical strategy -- Positive ongoing discussions with ...

Less than 24 hours after throwing 4 1/3 innings in his minor league rehabilitation start for Double-A Somerset, New York ...

Aurion Biotech, Inc. ("Aurion Biotech"), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...